Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin vs Rivaroxaban after Bioprosthetic Aortic Valve Replacement
NCT02974920Phase 4Unknown
- Start
- Jan 2017
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in thrombosis. Primary endpoint: Combined event of all-cause mortality and hospitalisation for acute myocardial infarction or stroke at 6 months. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT02974920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974920.